In NAFLD patients, TM6SF2 E167K is associated with significant fibrosis (stages 2–4), with an odds ratio (OR) of 1.88, independent of the PNPLA3 genotype [113]. This evidence concerns the gene TM6SF2 and metabolic dysfunction-associated steatotic liver disease.